.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

MYLOTARG Drug Profile

« Back to Dashboard
Mylotarg is a drug marketed by Wyeth Pharms Inc and is included in one NDA.

The generic ingredient in MYLOTARG is gemtuzumab ozogamicin. Additional details are available on the gemtuzumab ozogamicin profile page.

Summary for Tradename: MYLOTARG

Patents:0
Applicants:1
NDAs:1

Clinical Trials for: MYLOTARG

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Inc
MYLOTARG
gemtuzumab ozogamicin
INJECTABLE;INJECTION021174-001May 17, 2000DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: MYLOTARG

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms Inc
MYLOTARG
gemtuzumab ozogamicin
INJECTABLE;INJECTION021174-001May 17, 20005,773,001<disabled>
Wyeth Pharms Inc
MYLOTARG
gemtuzumab ozogamicin
INJECTABLE;INJECTION021174-001May 17, 20004,970,198<disabled>
Wyeth Pharms Inc
MYLOTARG
gemtuzumab ozogamicin
INJECTABLE;INJECTION021174-001May 17, 20005,693,762<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc